Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 4/2014

01-04-2014 | Research Article

The effects of p53 Arg72Pro polymorphism on glioma susceptibility: a meta-analysis

Authors: Weijie Zhu, Lei Lu, Yi Li, Jie Yao, Bainan Xu

Published in: Tumor Biology | Issue 4/2014

Login to get access

Abstract

The potentially functional polymorphism Arg72Pro in p53 gene has been implicated in glioma risk, but published studies have mixed findings. The aim of current investigation was to identify whether p53 Arg72Pro polymorphism was significantly associated with the risk of glioma. By searching the databases of PubMed, EMBASE, and Web of Science, our meta-analysis included ten eligible studies consisting of 2,645 glioma cases and 3,920 control subjects. The association between p53 Arg72Pro polymorphism and glioma risk was assessed by summarizing the odds ratios (ORs) with the corresponding 95 % confidence intervals (CIs). We found that there was no overall risk of glioma in relation to any genetic model of p53 Arg72Pro polymorphism. Similar results were implicated in the analyses which are subgrouped by ethnicity and source of controls. This nonsignificant association remained stable when analyses were restrained to the studies consistent with HWE. In conclusion, our meta-analysis, based on the combined data from published papers before May 2013, reveals no evidence for significant association between p53 Arg72Pro polymorphism and glioma risk.
Literature
1.
Hess KR, Broglio KR, Bondy ML. Adult glioma incidence trends in the United States, 1977-2000. Cancer. 2004;101(10):2293–9.PubMedCrossRef
2.
Ron E et al. Tumors of the brain and nervous system after radiotherapy in childhood. N Engl J Med. 1988;319(16):1033–9.PubMedCrossRef
3.
Thomas TL et al. Brain tumor mortality risk among men with electrical and electronics jobs: a case-control study. J Natl Cancer Inst. 1987;79(2):233–8.PubMed
4.
Inskip PD, Linet MS, Heineman EF. Etiology of brain tumors in adults. Epidemiol Rev. 1995;17(2):382–414.PubMed
5.
Bondy ML et al. Mutagen sensitivity and risk of gliomas: a case-control analysis. Cancer Res. 1996;56(7):1484–6.PubMed
6.
Bondy ML et al. Gamma-radiation sensitivity and risk of glioma. J Natl Cancer Inst. 2001;93(20):1553–7.PubMedCrossRef
7.
Ruttan CC, Glickman BW. Coding variants in human double-strand break DNA repair genes. Mutat Res. 2002;509(1–2):175–200.PubMedCrossRef
8.
Dasika GK et al. DNA damage-induced cell cycle checkpoints and DNA strand break repair in development and tumorigenesis. Oncogene. 1999;18(55):7883–99.PubMedCrossRef
9.
10.
Ehrlich M, Zhang XY, Inamdar NM. Spontaneous deamination of cytosine and 5-methylcytosine residues in DNA and replacement of 5-methylcytosine residues with cytosine residues. Mutat Res. 1990;238(3):277–86.PubMedCrossRef
11.
Jin S, Levine AJ. The p53 functional circuit. J Cell Sci. 2001;114(Pt 23):4139–40.PubMed
12.
13.
Parhar P et al. Possible association of p53 codon 72 polymorphism with susceptibility to adult and pediatric high-grade astrocytomas. Brain Res Mol Brain Res. 2005;137(1–2):98–103.PubMedCrossRef
14.
Jin T, Zhang J, Li G, Li S, Yang B, Chen C, et al. TP53 and RPA3 gene variations were associated with risk of glioma in a Chinese Han population. Cancer Biother Radiopharm. 2013;28(3):248–53.PubMedCrossRef
15.
Malmer BS et al. Genetic variation in p53 and ATM haplotypes and risk of glioma and meningioma. J Neurooncol. 2007;82(3):229–37.PubMedCrossRef
16.
El HS et al. TP53 codon 72 polymorphism is associated with age at onset of glioblastoma. Neurology. 2009;72(4):332–6.CrossRef
17.
Wang LE et al. Polymorphisms of DNA repair genes and risk of glioma. Cancer Res. 2004;64(16):5560–3.PubMedCrossRef
18.
Rajaraman P et al. Polymorphisms in apoptosis and cell cycle control genes and risk of brain tumors in adults. Cancer Epidemiol Biomarkers Prev. 2007;16(8):1655–61.PubMedCrossRef
19.
Idbaih A et al. Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors. Brain Res. 2008;1198:16–20.PubMedCrossRef
20.
Pinto GR et al. Prognostic value of TP53 Pro47Ser and Arg72Pro single nucleotide polymorphisms and the susceptibility to gliomas in individuals from Southeast Brazil. Genet Mol Res. 2008;7(1):207–16.PubMedCrossRef
21.
Lima-Ramos V et al. TP53 codon 72 polymorphism in susceptibility, overall survival, and adjuvant therapy response of gliomas. Cancer Genet Cytogenet. 2008;180(1):14–9.PubMedCrossRef
22.
Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med. 1997;127(9):820–6.PubMedCrossRef
23.
Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719–48.PubMed
24.
25.
26.
Idbaih A et al. Tumor genomic profiling and TP53 germline mutation analysis of first-degree relative familial gliomas. Cancer Genet Cytogenet. 2007;176(2):121–6.PubMedCrossRef
27.
Faria MH et al. TP53 mutations in astrocytic gliomas: an association with histological grade, TP53 codon 72 polymorphism and p53 expression. APMIS. 2012;120(11):882–9.PubMedCrossRef
28.
Portwine C et al. Absence of germline and somatic p53 alterations in children with sporadic brain tumors. J Neurooncol. 2001;52(3):227–35.PubMedCrossRef
29.
30.
Iijima, J., et al., [Detection of codon 72 polymorphism of p53 gene from blood and loss of heterozygosity in brain tumors using polymerase chain reaction]. No To Shinkei, 1993. 45(1): p. 43-7.
31.
Zawlik I et al. Common polymorphisms in the MDM2 and TP53 genes and the relationship between TP53 mutations and patient outcomes in glioblastomas. Brain Pathol. 2009;19(2):188–94.PubMedCrossRef
32.
Jha P et al. TP53 polymorphisms in gliomas from Indian patients: study of codon 72 genotype, rs1642785, rs1800370 and 16 base pair insertion in intron-3. Exp Mol Pathol. 2011;90(2):167–72.PubMedCrossRef
33.
Shete S et al. Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet. 2009;41(8):899–904.PubMedCrossRef
34.
35.
Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature, 2008. 455(7216): p. 1061-8.
36.
37.
Malmer B et al. p53 Genotypes and risk of glioma and meningioma. Cancer Epidemiol Biomarkers Prev. 2005;14(9):2220–3.PubMedCrossRef
38.
He F et al. P53 codon 72 Arg/Pro polymorphism and glioma risk: an updated meta-analysis. Tumor Biol. 2013;34:3121–30.CrossRef
39.
Higgins J.P.T., Greens S., Cochrane handbook for systematic reviews of intervention version 5.1.0 [updated March 2011]. The Cochrane collaboration, 2011. Available from www.​cochrane-handbook.​org.Accessed 30 May 2013.
Metadata
Title
The effects of p53 Arg72Pro polymorphism on glioma susceptibility: a meta-analysis
Authors
Weijie Zhu
Lei Lu
Yi Li
Jie Yao
Bainan Xu
Publication date
01-04-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 4/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1494-4

Other articles of this Issue 4/2014

Tumor Biology 4/2014 Go to the issue

Research Article

EMP1, a member of a new family of antiproliferative genes in breast carcinoma

Research Article

Cytochrome b5 reductase 2 is a novel candidate tumor suppressor gene frequently inactivated by promoter hypermethylation in human nasopharyngeal carcinoma

Research Article

The variant interleukin 1f7 rs3811047 G>A was associated with a decreased risk of gastric cardiac adenocarcinoma in a Chinese Han population

Research Article

Decorin-mediated inhibition of cholangiocarcinoma cell growth and migration and promotion of apoptosis are associated with E-cadherin in vitro

Research Article

Hexokinase 2 overexpression promotes the proliferation and survival of laryngeal squamous cell carcinoma

Review

The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits